Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 4:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 4,718 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Allergies Clear all
Completed Phase 3 Interventional Results available

Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 1 (ECZema TRAlokinumab Trial no. 1)

NCT03131648
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Tralokinumab, Placebo
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
802 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
44
States / cities
Birmingham, Alabama • Fountain Valley, California • Los Angeles, California + 37 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2025 · Synced Jun 10, 2026, 4:23 PM EDT
Completed Phase 1 Interventional

Pharmacokinetics of C1 Esterase Inhibitor in Hereditary Angioedema Subjects

NCT00432510
View directory record Official record
Conditions
Hereditary Angioedema
Interventions
C1 esterase inhibitor [human] (C1INH-nf)
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
6
States / cities
San Diego, California • Walnut Creek, California • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2021 · Synced Jun 10, 2026, 4:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Hearing Study: Sensitivity to Features of Speech Sounds

NCT03666676
View directory record Official record
Conditions
Hearing Loss, Sensorineural
Interventions
Signal processing to improve intelligibility
Other
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 80 Years
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated May 28, 2025 · Synced Jun 10, 2026, 4:23 PM EDT
Completed Not applicable Interventional

ASTHMA-Educator Mobile Application Manage Asthma

NCT03518879
View directory record Official record
Conditions
Asthma
Interventions
ASTHMA-Educator mobile application
Other
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jun 6, 2023 · Synced Jun 10, 2026, 4:23 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of Tezepelumab in Reducing Oral Corticosteroid Use in Adults With Oral Corticosteroid Dependent Asthma

NCT03406078
View directory record Official record
Conditions
Asthma
Interventions
Tezepelumab, Placebo
Biological · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 80 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
21
States / cities
Bakersfield, California • Newark, Delaware • Kissimmee, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2021 · Synced Jun 10, 2026, 4:23 PM EDT
Completed Phase 3 Interventional

To Assess the Safety and Efficacy of Ciclesonide Applied as a Nasal Spray in the Treatment of Perennial Allergic Rhinitis (BY9010/M1-402)

NCT00659750
View directory record Official record
Conditions
Rhinitis, Allergic, Perennial
Interventions
Ciclesonide, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years and older
Enrollment
418 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
23
States / cities
Encinitas, California • Long Beach, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2016 · Synced Jun 10, 2026, 4:23 PM EDT
Not listed No phase listed Observational

Creation of Home-based Asthma Real-World Measures With Mobile Health Study

NCT04462224
View directory record Official record
Conditions
Asthma
Interventions
Not listed
Lead sponsor
National Jewish Health
Other
Eligibility
18 Years to 85 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 22, 2021 · Synced Jun 10, 2026, 4:23 PM EDT
Completed No phase listed Observational

A Study to Assess the Reliability/Feasibility of Using Emerald Touchless Sensor for Scratching and Sleep Quantification in a Subset of Participants From PEDISTAD Study (OBS15333; NCT03687359)

NCT05235724
View directory record Official record
Conditions
Dermatitis Atopic
Interventions
Not listed
Lead sponsor
Sanofi
Industry
Eligibility
6 Years to 11 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
7
States / cities
Montgomery, Alabama • Hialeah, Florida • Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2023 · Synced Jun 10, 2026, 4:23 PM EDT
Completed Phase 2 Interventional Results available

The Safety of Administering a Second Dose of a COVID-19 mRNA Vaccine in Individuals Who Experienced a Systemic Allergic Reaction to an Initial Dose

NCT04977479
View directory record Official record
Conditions
Systemic Allergic Reaction
Interventions
Pfizer-BioNTech COVID-19 Vaccine (Comirnaty), Placebo, Pfizer-BioNTech COVID-19 Vaccine, Bivalent
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
16 Years to 69 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 15, 2023 · Synced Jun 10, 2026, 4:23 PM EDT
Terminated Phase 2 Interventional Results available

Food Allergen OIT for Shrimp and Cashew

NCT03504774
View directory record Official record
Conditions
Allergy;Food, Allergy to Shrimp, Allergy to Cashew Nut (Disorder)
Interventions
Cashew or Shrimp Oral Immunotherapy
Drug
Lead sponsor
Sayantani B. Sindher
Other
Eligibility
7 Years to 55 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Apr 26, 2026 · Synced Jun 10, 2026, 4:23 PM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Study of Focal Airway Disease in Asthma Using Image Guided Bronchoscopy

NCT04514913
View directory record Official record
Conditions
Asthma, Mucus; Plug, Tracheobronchial
Interventions
Multidetector Computed Tomography (MDCT) Scan, Virtual Navigation Bronchoscopy (VNB)
Radiation · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Jun 10, 2026, 4:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Trial to Assess Full-fat or Low-fat Dairy Foods on Insulin Sensitivity, RBC FA's and Other Markers of Metabolic Health

NCT04999462
View directory record Official record
Conditions
Overweight and Obesity, Elevated Triglycerides
Interventions
Full-fat fermented dairy, Low-fat fermented dairy, Non-dairy, non-fermented foods
Other
Lead sponsor
Midwest Center for Metabolic and Cardiovascular Research
Other
Eligibility
18 Years to 74 Years
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
4
States / cities
Miami Gardens, Florida • Chicago, Illinois • Gurnee, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 5, 2025 · Synced Jun 10, 2026, 4:23 PM EDT
Completed Not applicable Interventional

Factors Influencing Pediatric Asthma

NCT03302962
View directory record Official record
Conditions
Asthma in Children
Interventions
Intensive Asthma Education
Behavioral
Lead sponsor
Missouri Breaks Industries Research, Inc.
Other
Eligibility
6 Years to 17 Years
Enrollment
324 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Eagle Butte, South Dakota
Source: ClinicalTrials.gov public record
Updated Oct 4, 2017 · Synced Jun 10, 2026, 4:23 PM EDT
Completed Not applicable Interventional Results available

Pulmonary Specialist-Health Coach Consult Model Study

NCT03695276
View directory record Official record
Conditions
COPD Asthma
Interventions
PushCon Model, Usual care
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
328 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
11
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Jun 10, 2026, 4:23 PM EDT
Active, not recruiting Not applicable Interventional

A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)

NCT03927820
View directory record Official record
Conditions
COPD, Asthma
Interventions
Benefits investigation
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
914 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 28, 2025 · Synced Jun 10, 2026, 4:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Evaluation of the Safety and Efficacy of an Oxalate Gel or Negative Control on Dentinal Hypersensitivity

NCT02189382
View directory record Official record
Conditions
Dentin Sensitivity
Interventions
Potassium Oxalate, Water
Device · Other
Lead sponsor
Procter and Gamble
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Aug 19, 2018 · Synced Jun 10, 2026, 4:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Light Sensitization Study

NCT01327040
View directory record Official record
Conditions
Chronobiology Disorders, Circadian Rhythm Disorders, Sleep Disorders, Circadian Rhythm
Interventions
light exposure
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
21 Years to 30 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 30, 2021 · Synced Jun 10, 2026, 4:23 PM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Study to Evaluate the Safety and Efficacy of Intravenously Administered Benralizumab (MEDI-563).

NCT00768079
View directory record Official record
Conditions
Asthma
Interventions
Placebo, Benralizumab
Other · Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 60 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
9
States / cities
Tampa, Florida • Springfield, Massachusetts • Detroit, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2020 · Synced Jun 10, 2026, 4:23 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1b Study Assessing the PK, PD, Safety & Tolerability of SB414 in Atopic Dermatitis

NCT03431610
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
SB414 2%, SB414 6%, Vehicle
Drug
Lead sponsor
Novan, Inc.
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
9
States / cities
Coral Gables, Florida • Sweetwater, Florida • Boise, Idaho + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 6, 2018 · Synced Jun 10, 2026, 4:23 PM EDT
Not listed Not applicable Interventional

Effect of Omalizumab (Xolair) in Treatment of Patients With AERD and Allergy Asthma

NCT00286416
View directory record Official record
Conditions
Asthma, Allergic Rhinitis
Interventions
omalizumab (Xolair)
Drug
Lead sponsor
Scripps Clinic
Other
Eligibility
18 Years to 90 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Nov 6, 2006 · Synced Jun 10, 2026, 4:23 PM EDT
Recruiting Not applicable Interventional

Reciprocal Imitation Training and Musical Rhythm Sensitivity in Autistic Toddlers

NCT05880225
View directory record Official record
Conditions
Autism, Autism Spectrum Disorder
Interventions
Reciprocal Imitation Training, music-enhanced Reciprocal Imitation Training
Behavioral
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Months to 36 Months
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Jun 10, 2026, 4:23 PM EDT
Terminated Phase 2 Interventional Results available

A Study of LY3375880 in Adults With Moderate-to-Severe Atopic Dermatitis

NCT03831191
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
LY3375880, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
14
States / cities
Fountain Valley, California • Los Angeles, California • Northridge, California + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2021 · Synced Jun 10, 2026, 4:23 PM EDT
Completed Phase 3 Interventional Results available

A Study of the Efficacy and Safety of Omalizumab (Xolair) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine (H1) Treatment

NCT01287117
View directory record Official record
Conditions
Chronic Idiopathic Urticaria
Interventions
Omalizumab, Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
12 Years to 75 Years
Enrollment
319 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
40
States / cities
Birmingham, Alabama • Huntington Beach, California • Long Beach, California + 37 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2013 · Synced Jun 10, 2026, 4:23 PM EDT
Completed Phase 4 Interventional Results available

Comparison Between Systemic Exposure to Ciclesonide Nasal Spray, Ciclesonide HFA Nasal Aerosol and Orally Inhaled Ciclesonide (BY9010/M1-422)

NCT00458835
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
Ciclesonide
Drug
Lead sponsor
Covis Pharma S.à.r.l.
Industry
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Jun 10, 2026, 4:23 PM EDT